Phathom Pharmaceuticals Inc (PHAT) Stock Price, Quote & News

Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heart...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 742 8466

Website: www.phathompharma.com

Address:

100 Campus Drive, Suite 102, Florham Park, United States

Withermania Aug. 4 at 7:33 PM

$PHAT interest rates going lower, expenses going down, prescriptions surging, revenue surging…low float. Shareholders are going to shepherd a sale here to Astra Zeneca

0 · Reply

fgggggggg Aug. 4 at 2:21 PM

$PHAT BO in next 3-4 quarters. $40-50 per share. I will wait for that.

0 · Reply

Walleyeslayer Aug. 4 at 1:00 PM

$PHAT welp! Feast or famine? I’m leaning toward feast. Increased script numbers. Increased revenue. Cost cutting in place. Excited to see it run but will wait another quarter if needed. 😀

1 · Reply

fgggggggg Aug. 4 at 12:34 PM

$PHAT

0 · Reply

Ecryder Aug. 4 at 12:23 PM

$PHAT

0 · Reply

Withermania Aug. 3 at 5:57 PM

$PHAT Big week. Q1 revs sucked but insurance issues always delay payments and small early commercial stage are susceptible. I think revs come in over $42MM for Q2 given Q1 roll over payments. If we get a really big number, the fomo to acquire $PHAT could be intense.

1 · Reply

longshot45 Jul. 31 at 6:42 PM

$PHAT Another huge swing day. Though today seems like it was caused by short selling based on the drop in shares available to short

0 · Reply

fgggggggg Jul. 31 at 6:33 PM

$PHAT anyone have the script numbers

0 · Reply

Hendo111 Jul. 31 at 5:07 PM

$PHAT ✅

0 · Reply

Jacobi Jul. 31 at 1:22 PM

$PHAT 8/7 $AKBA

0 · Reply

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Jun 25, 2025, 4:54 AM EDT - 5 weeks ago

Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism

Jun 23, 2025, 4:15 PM EDT - 6 weeks ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 23, 2025, 7:59 AM EDT - 6 weeks ago

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

SAGE

Jun 16, 2025, 8:00 AM EDT - 7 weeks ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Jun 10, 2025, 10:08 AM EDT - 7 weeks ago

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy

Jun 6, 2025, 12:27 PM EDT - 2 months ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

May 15, 2025, 7:59 AM EDT - 2 months ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

May 1, 2025, 12:09 PM EDT - 3 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 3 months ago

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ITCI

Apr 28, 2025, 7:59 AM EDT - 3 months ago

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Apr 23, 2025, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Apr 17, 2025, 8:00 AM EDT - 3 months ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

HLVX

Apr 16, 2025, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

CDTX

Apr 3, 2025, 8:00 AM EDT - 4 months ago

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 4 months ago

Phathom Pharmaceuticals Announces Leadership Succession

Mar 31, 2025, 7:59 AM EDT - 4 months ago

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Mar 6, 2025, 12:13 PM EST - 5 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 8:00 AM EST - 5 months ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:00 AM EST - 5 months ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Jan 29, 2025, 8:00 AM EST - 6 months ago

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Dec 11, 2024, 8:00 AM EST - 8 months ago

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Nov 10, 2024, 3:54 AM EST - 9 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript

Oct 28, 2024, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Oct 27, 2024, 12:00 PM EDT - 10 months ago

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Aug 10, 2024, 2:52 PM EDT - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Jun 26, 2024, 6:11 AM EDT - 1 year ago

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

May 11, 2024, 7:03 PM EDT - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript

May 9, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Mar 18, 2024, 1:19 AM EDT - 1 year ago

Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion

Mar 7, 2024, 2:11 PM EST - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 29, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

Jan 31, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 1, 2024, 6:41 AM EST - 1 year ago

Phathom Pharma Is A Buy Before July PDUFA

Dec 6, 2023, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

Nov 28, 2023, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

Nov 9, 2023, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

Nov 1, 2023, 5:00 PM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

Oct 30, 2023, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

Oct 5, 2023, 12:43 PM EDT - 1 year ago

Following Up On Phathom Pharmaceuticals

Sep 26, 2023, 8:01 AM EDT - 2 years ago

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

Aug 21, 2023, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

Aug 10, 2023, 8:01 AM EDT - 2 years ago

Phathom Pharmaceuticals Reports Second Quarter 2023 Results

Withermania Aug. 4 at 7:33 PM

$PHAT interest rates going lower, expenses going down, prescriptions surging, revenue surging…low float. Shareholders are going to shepherd a sale here to Astra Zeneca

0 · Reply

fgggggggg Aug. 4 at 2:21 PM

$PHAT BO in next 3-4 quarters. $40-50 per share. I will wait for that.

0 · Reply

Walleyeslayer Aug. 4 at 1:00 PM

$PHAT welp! Feast or famine? I’m leaning toward feast. Increased script numbers. Increased revenue. Cost cutting in place. Excited to see it run but will wait another quarter if needed. 😀

1 · Reply

fgggggggg Aug. 4 at 12:34 PM

$PHAT

0 · Reply

Ecryder Aug. 4 at 12:23 PM

$PHAT

0 · Reply

Withermania Aug. 3 at 5:57 PM

1 · Reply

longshot45 Jul. 31 at 6:42 PM

$PHAT Another huge swing day. Though today seems like it was caused by short selling based on the drop in shares available to short

0 · Reply

fgggggggg Jul. 31 at 6:33 PM

$PHAT anyone have the script numbers

0 · Reply

Hendo111 Jul. 31 at 5:07 PM

$PHAT ✅

0 · Reply

Jacobi Jul. 31 at 1:22 PM

$PHAT 8/7 $AKBA

0 · Reply

PolymathMan Jul. 30 at 7:04 PM

$PHAT Someone is angweeeee😂😂😂😂😂😂😂😂

0 · Reply

Walleyeslayer Jul. 30 at 5:33 PM

$PHAT Let the games begin!

2 · Reply

ScottyDoesntKnowMeSon Jul. 29 at 3:37 PM

$PHAT retest complete. Let’s see where we go

1 · Reply

Withermania Jul. 29 at 2:40 PM

$PHAT tick tock…tick tock…revenues are going to come in solid and this company is back on track following the patent issue. This should be sitting at $20 a share currently.

1 · Reply

PHATwillmoon Jul. 29 at 3:26 AM

$PHAT Why would physicians write prescriptions for something a patient can get over the counter? Patients already had that option, they’re seeing the doctor because they need something else. Voquezna will eventually be the only thing physicians precribe.

0 · Reply

Walleyeslayer Jul. 28 at 8:00 PM

$PHAT Pushing it down so they can buy it back up. Hold tight all.

1 · Reply